Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07264517 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
A Phase 2 study of Dry Eye Disease, sponsored by Instituto Grifols, S.A..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 10
- Study locations
NCT07264517 is a Phase 2 study of Dry Eye Disease that is actively recruiting participants, run by Instituto Grifols, S.A.. The registered enrollment target is 100 participants, below the 252-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (60% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT07264517, a Phase 2 study of Dry Eye Disease, is actively recruiting participants, sponsored by Instituto Grifols, S.A..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Phase 2, multi-site, double-masked, randomized, vehicle-controlled, study designed to evaluate the safety, tolerability, and efficacy in adult participants with DED.
Conditions Studied
Interventions
- DRUG GRF312 5%
- OTHER Placebo Comparator
Study Locations (10)
California
- GC2302 Study Site 110 - Glendale
- GC2302 Study Site 109 - Grove
- GC2302 Study Site 103 - Newport Beach
North Carolina
- GC2302 Study Site 104 - Asheville
- GC2302 Study Site 101 - Garner
Georgia
- GC2302 Study Site 105 - Morrow
Indiana
- GC2302 Study Site 106 - Carmel
Pennsylvania
- GC2302 Study Site 107 - Cranberry Township
Tennessee
- GC2302 Study Site 102 - Memphis
Texas
- GC2302 Study Site 111 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2026-11-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07264517
The ClinicalTrials.gov registry entry for NCT07264517 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 252-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (60% lower). The listed sponsor is Instituto Grifols, S.A., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which GRF312 5% is the first listed.
NCT07264517 reports 10 study locations spanning 7 distinct geographic areas - top geographies include California, North Carolina, Georgia.
Frequently Asked Questions
What is clinical trial NCT07264517 about?
NCT07264517 is a clinical study titled "Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).". This is a Phase 2, multi-site, double-masked, randomized, vehicle-controlled, study designed to evaluate the safety, tolerability, and efficacy in adult participants with DED.
What is the current status of trial NCT07264517?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-11-03. Estimated completion is 2026-11-14.
What conditions does trial NCT07264517 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT07264517?
The interventions under investigation include: GRF312 5% (DRUG), Placebo Comparator (OTHER).
Who is sponsoring clinical trial NCT07264517?
This trial is sponsored by Instituto Grifols, S.A., which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07264517 being conducted?
This trial has 10 study locations across California, Georgia, Indiana, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
RECRUITING · Phase 2
-
Phase 2b Controlled Study
ACTIVE NOT RECRUITING · Phase 2
-
A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease
ACTIVE NOT RECRUITING · Phase 2
-
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
COMPLETED · Phase 2
-
A Study of TL-925 as a Treatment for Dry Eye Disease
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.